2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) …

IC Van Gelder, M Rienstra, KV Bunting… - European Heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

B Vogel, M Acevedo, Y Appelman, CNB Merz… - The Lancet, 2021 - thelancet.com
Cardiovascular disease is the leading cause of death in women. Decades of grassroots
campaigns have helped to raise awareness about the impact of cardiovascular disease in …

Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation

P Osmancik, D Herman, P Neuzil, P Hala… - Journal of the American …, 2020 - jacc.org
Background Percutaneous left atrial appendage closure (LAAC) is noninferior to vitamin K
antagonists (VKAs) for preventing atrial fibrillation (AF)–related stroke. However, direct oral …

EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion–an update

M Glikson, R Wolff, G Hindricks, J Mandrola… - EP …, 2020 - academic.oup.com
This article has been co-published with permission in EP Europace and EuroIntervention. All
rights reserved. VC 2019 the European Heart Rhythm Association and the European …

5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials

VY Reddy, SK Doshi, S Kar, DN Gibson… - Journal of the American …, 2017 - jacc.org
Abstract Background: The PROTECT AF (WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial …

[HTML][HTML] Фибрилляция и трепетание предсердий. Клинические рекомендации 2020

МГ Аракелян, ЛА Бокерия, ЕЮ Васильева… - Российский …, 2021 - cyberleninka.ru
Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

[HTML][HTML] 2020 Clinical guidelines for Atrial fibrillation and atrial flutter

MG Arakelyan, LA Bockeria… - Russian Journal of …, 2021 - russjcardiol.elpub.ru
clinical guidelines, atrial fibrillation, ischemic stroke, anticoagulant therapy, vitamin K
antagonists, direct oral anticoagulants, triple antiplatelet therapy, rhythm control, electrical …

2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or …

GYH Lip, JP Collet, M Haude, R Byrne, EH Chung… - Ep …, 2019 - academic.oup.com
In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

[HTML][HTML] Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up …

LV Boersma, H Ince, S Kische, E Pokushalov… - Heart rhythm, 2017 - Elsevier
Background Left atrial appendage (LAA) occlusion with WATCHMAN has emerged as viable
alternative to vitamin K antagonists in randomized controlled trials. Objective EWOLUTION …

Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation

L Fauchier, A Cinaud, F Brigadeau, A Lepillier… - Journal of the American …, 2018 - jacc.org
Background: Transcatheter left atrial appendage (LAA) occlusion is an alternative strategy
for stroke prevention in patients with atrial fibrillation (AF). Objectives: This study sought to …